30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

More 2010 Results: NuVasive

NUVASIVE
$478.2MM, +29%

4Q10 revenue: $129.3MM, +21%

* Lumbar spinal fusion procedure volumes still depressed
* Reimbursement situation improved, all major payers shifted back to positive coverage
* Settled patent dispute with Orthofix relative to Osteocel, entered into a license agreement covering Trinity Evolution; also entered into recent licensing agreement with AlloSource for allograft stem cell product
* Expecting ex-U.S. business to double in 2011; cross-selling opportunities exceptionally robust
* Preparing to open Tokyo office in early 2012
* Update on PCM cervical disc and Progentix synthetic biologic: may be commercialized late 2011, early 2012
* PCM not likely to require FDA panel meeting; approval would put company in 3rd or 4th place in U.S. in cervical discs
* Sales force currently in the 300s